Selected Drugs Clear All
MultiCheck Results
- 1
Interaction
Avoid/Use Alternative |
||
|
Nucynta ER
(tapentadol) + Zubsolv
(buprenorphine/ naloxone) |
||
Avoid/Use Alternativetapentadol + buprenorphine use alternative or monitor respiratory rate, BP, withdrawal symptoms, serotonin syndrome symptoms, especially during initiation/titration; decrease dose of one or both drugs, use lowest effective doses and shortest duration of concomitant treatment: combo may increase risk of profound CNS and respiratory depression, psychomotor impairment, severe hypotension (including orthostasis, syncope), serotonin syndrome, severe constipation, paralytic ileus; may decrease tapentadol efficacy, precipitate withdrawal in opioid dependent patients (additive effects; antagonistic effects) |
||
Additional Considerations |
||
|
tapentadol
in Nucynta ER
|
||
|
consider prescribing an opioid overdose reversal agent, especially with concomitant CNS depressant use add MAO inhibitor to Interaction Check if recent (14 days) use avoid combo with beverages or products containing ethanol and tapentadol extended-release (ER) tablets; combo may incr. tapentadol release rate, levels, risk of adverse effects, including life-threatening overdose, decr. duration of efficacy |
||
|
buprenorphine
in Zubsolv
|
||
|
consider prescribing an opioid overdose reversal agent, especially with concomitant CNS depressant use |
||
|
naloxone (abuse deterrent)
in Zubsolv
|
||
|
no pharmacologic activity when administered as directed |
||